<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853710</url>
  </required_header>
  <id_info>
    <org_study_id>ID RCB 2008-A01497-48</org_study_id>
    <secondary_id>CRH 08/459/MN</secondary_id>
    <nct_id>NCT00853710</nct_id>
  </id_info>
  <brief_title>Test Semiquantitative Prostate Specific Antigen (PSA)</brief_title>
  <official_title>Validation of a Semiquantitative Screening Assay for PSA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the diagnostic performances of a simple and rapid PSA
      assay on whole blood to the standard plasma PSA assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening and surveillance of prostate cancer typically involves sensitive laboratory
      techniques for the quantification of plasma prostate specific antigen (PSA). In this study,
      we determine the sensitivity and specificity of a simple test strip based PSA assay using
      only a few drops of whole blood as compared to a standard plasma PSA assay. Blood samples
      will be taken from hundred patients who are followed for a prostatic disease needing PSA
      surveillance. Before decantation of the samples, a few drops of blood will serve for the
      rapid test on strips. Plasma PSA levels will be determined with the TRACE (&quot;Time Resolved
      Amplified Cryptate Emission&quot;) technology in homogeneous liquid phase. The results from the
      rapid test can then be compared to the plasma levels obtained by TRACE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the sensitivity and specificity of the rapid PSA assay by comparing the results obtained from the test strip reading by three independent blinded observers with those from standard plasma PSA assay.</measure>
    <time_frame>day of test</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the threshold which maximizes the performance of the semiquantitative test. Determination of interobserver agreement.</measure>
    <time_frame>at the last inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostatic Diseases</condition>
  <arm_group>
    <arm_group_label>rapid PSA assay on whole blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PSA assay</intervention_name>
    <description>rapid prostate specific antigen assay.</description>
    <arm_group_label>rapid PSA assay on whole blood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients followed for prostate cancer or symptomatic benign prostatic disease, and for
             who a PSA assay is indicated.

          -  Patients must have given informed consent.

        Exclusion Criteria:

          -  Patients followed for a disease other than prostatic.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique BELLET, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate-Specific Antigen</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

